

ISFTD 2024 POSTER PRESENTATIONS



Schedule poster presentations	
P001-P116	Day 1 Thursday, 19 September
P125-P257	Day 2 Friday, 20 September
P275-P257	Day 3 Saturday, 21 September
P400-P427	Caregivers Day, Saturday 21 September + Day 4, Sunday 22 September

Paper Reference	Paper Title	Theme	Submitted by: Name	Last Name	Secondary Address - Country	Presenting Author Names
P014	Decreased Employment Status Linked to Frontotemporal Dementia and Early Onset Alzheimer's Disease 10 Years Before the Diagnosis	01. Epidemiology	Ave	Kivisild	Finland	specialist neurologist Ave Kivisild
P015	Time to diagnosis and its predictors in Frontotemporal Lobar Degeneration	01. Epidemiology	Valeria	Bracca	Italy	Ms. Valeria Bracca
P016	Using real-world-data to characterize common diagnoses among patients with frontotemporal dementia in the United States	01. Epidemiology	Harjeet	Dhillon	United Kingdom	Harjeet Dhillon
P017	GENFI - Neurodevelopment	01. Epidemiology	Kristy	Coleman	Canada	Kristy Coleman
P018	Occupational exposures modify longitudinal decline in frontotemporal degeneration	01. Epidemiology	Lauren	Massimo	United States	Lauren Massimo
P019	Lifelong health and well-being factors impacting age at symptom onset in genetic FTD	01. Epidemiology	Jessica	Panman	Netherlands	Dr. Jessica Panman
P020	The effect of deprivation on absolute and independent survival in frontotemporal lobar degeneration syndromes	01. Epidemiology	Anna Jane	Dreyer	United Kingdom	Dr Anna Jane Dreyer
P021	Exploration of tonic recruitment and apathy in people living with frontotemporal dementia within ecological settings	01. Epidemiology	Elena	Karpinski	France	Elena Karpinski
P022	10 years of PiPPIN- an epidemiological cohort study of syndromes associated with Frontotemporal Lobar Degeneration	01. Epidemiology	Katherine	Stockton	United Kingdom	Dr Katherine Stockton
P023	EFRONT (EPIDEMIOLOGICAL STUDY IN FRONTOTEMPORAL DEMENTIA): Design and Preliminary Findings	01. Epidemiology	Jefri	Jeya Paul	Germany	Dr. Jefri Jeya Paul
P024	Disease-modifying factors in frontotemporal dementia: a systematic review	01. Epidemiology	Thamires	Marx Da Silva Santos	Brazil	Dr Thamires Marx Da Silva Santos
P025	Cross-cultural Comparison of Early Behavioral Changes in bvFTD	01. Epidemiology	Fan	Ji	Belgium	Fan Ji
P026	GEOGRAPHIC BIAS IN HAND PREFERENCE WITHIN POSTERIOR CORTICAL ATROPHY, SEMANTIC DEMENTIA, AND TYPICAL AD	01. Epidemiology	Zachary	Miller	United States	Dr. Zachary Miller
P027	Improved Nonlinear Z-score Correction for Neuropsychological Testing of Patients with FTLD-Spectrum Disorders	01. Epidemiology	John	Kornak	United States	Professor John Kornak
P028	A novel approach to identify carriers of familial FTD variants via online channels	01. Epidemiology	Sergio	Bauer	Brazil	Sergio Bauer
P029	Greater neighborhood deprivation is related to shorter survival in behavioral-variant frontotemporal degeneration	01. Epidemiology	Rory	Boyle	United States	Rory Boyle
P030	The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration	02a. Fluid biomarkers	Rachel	Acuna-narvaez	United States	Rachel Acuna-narvaez
P032	miRNA expression in neuronal derived extracellular vesicles in bvFTD and PPD: the DIPPA-FTD study	02a. Fluid biomarkers	Chiara	Fenoglio	Italy	PhD Daniela Galimberti
P033	Association between CSF protein biomarkers and gray matter atrophy: a GENFI study	02a. Fluid biomarkers	Abbe	Ullgren	Sweden	Abbe Ullgren

P034	Neural Derived Extracellular Vesicles miRNA cargo and Neuroimaging Profiles in Frontotemporal Dementia and Bipolar Disorder	02a. Fluid biomarkers	Maria	Serpente	Italy	PhD Maria Serpente
P035	Brain volumetry and serum neurofilament light differentiate between behavioral variant frontotemporal dementia and major depression	02a. Fluid biomarkers	Leonie	Werner	Germany	Leonie Werner
P036	Proteomic profiles of underlying pathologies in genetic frontotemporal dementia.	02a. Fluid biomarkers	Aitana	Sogorb-Esteve	United Kingdom	Dr Aitana Sogorb-Esteve
P037	Inflammatory profiles in Frontotemporal Dementia: A GENFI study	02a. Fluid biomarkers	Katie	Thompson	United Kingdom	Katie Thompson
P038	Plasma proteomic changes in Progranulin mutations carriers on the novel NULISA platform.	02a. Fluid biomarkers	Valentina	Cantoni	Italy	Phd Valentina Cantoni
P039	Blood-based biomarkers in C9orf72: RNA-foci and DPRs in PBMCs	02a. Fluid biomarkers	Julie	De Houwer	Netherlands	Julie De Houwer
P040	NfL and GFAP in Frontotemporal Lobar Degeneration spectrum: data from a population-based registry	02a. Fluid biomarkers	Chiara	Zecca	Italia	Dr Chiara Zecca
P041	Blood and CSF GFAP associate with brain astrogliosis in autopsied frontotemporal lobar degeneration	02a. Fluid biomarkers	Katheryn	Cousins	United States	Research Assistant Professor Katheryn Cousins
P042	Plasma biomarkers in primary progressive aphasia using a fully-automated platform	02a. Fluid biomarkers	Jordi	Matias Guiu Antem	Spain	Dr Jordi Matias Guiu Antem
P043	Neuron and glia cell-free DNA blood concentration: A new class of peripheral biomarker of neurodegeneration	02a. Fluid biomarkers	Ramon	Landin-Romero	Australia	Associate Professor Ramon Landin-Romero
P044	Neurofilaments and progranulin are related to atrophy in frontotemporal lobar degeneration - A transdiagnostic study cross-validating atrophy and fluid biomarkers	02a. Fluid biomarkers	Matthias	Schroeter	Germany	Prof. Matthias Schroeter
P045	Stratification of frontotemporal lobar degeneration-related syndromes using plasma ptau217 for clinical trials	02a. Fluid biomarkers	Alexander	Murley	United Kingdom	Dr Alexander Murley
P046	Distinguishing bvFTD from psychiatric disorders using neuroimaging and NFL	02a. Fluid biomarkers	Sean	Coulborn	United States	Dr Sean Coulborn
P047	Fluid biospecimens and genetic data: new collection and dissemination pipelines serving the dementia research community	02a. Fluid biomarkers	Argentina	Lario Lago	United States	Phd Argentina Lario Lago
P050	CSF proteome profiling identifies novel biomarker panels for Frontotemporal Dementia	02a. Fluid biomarkers	Yanaika	Hok-A-Hin	Netherlands	Yanaika Hok-A-Hin
P052	Comparing the biomarker potential of plasma glial fibrillary acidic protein and neurofilament light in frontotemporal dementia spectrum disorders	02a. Fluid biomarkers	Tania	Gendron	United States	Dr. Tania Gendron
P053	Addressing inter-individual variability in CSF biomarker levels across neurodegenerative diseases	02a. Fluid biomarkers	Sara	Mravinacova	Sweden	Sara Mravinacova
P054	Blood Neurofilament light chain has limited value in differentiating frontotemporal dementia from primary psychiatric disorders.	02a. Fluid biomarkers	Tim	Van Langenhove	Belgium	Md, Phd Tim Van Langenhove
P055	Plasma microRNAs as biomarkers of presymptomatic stages of genetic FTD	02a. Fluid biomarkers	Lydia	Velzian	New Zealand	Mrs Lydia Velzian
P056	α -synuclein and TDP-43 seeding activities in the olfactory mucosa of a patient with GRN mutation	02a. Fluid biomarkers	Paola	Caroppo	Italy	Md, Phd Paola Caroppo
P057	StopFTD with digital behavior markers	03. Neuropsychology	Han	van Doorn	Nederland	Ing Han van Doorn

P058	Overt and subtle temporal motor impairments in PPA and bvFTD	03. Neuropsychology	Adam	Vogel	Australia	Professor Adam Vogel
P059	The Northwestern Anagram Test for Primary Progressive Aphasia: Computer Module (NAT-C)	03. Neuropsychology	Sandra	Weintraub	United States	Professor Sandra Weintraub
P061	Brain structural and functional correlates of the generation of combination of remote semantic associates in frontotemporal dementia	03. Neuropsychology	Victor	Altmayer	France	Dr Victor Altmayer
P062	The speech-to-song illusion in frontotemporal dementia and Alzheimer's disease	03. Neuropsychology	Jess	Jiang	United Kingdom	Dr Jess Jiang
P063	Sleep disturbance associated with temporal lobe degeneration in frontotemporal dementia	03. Neuropsychology	Jess	Jiang	United Kingdom	Dr Jess Jiang
P064	In depth comparison of the neuropsychological profile of primary psychiatric disorders and behavioral variant FTD	03. Neuropsychology	Agnes	Deneve	France	Agnes Deneve
P065	Scalar Implicatures in CBD and bvFTD Italian-Speaking Individuals: Preliminary Results	03. Neuropsychology	Silvia	De Marchi	United States	Silvia De Marchi
P066	The Eating Behavior Inventory (EBI) : a short questionnaire to distinguish behavioral frontotemporal	03. Neuropsychology	Carole	Azuar	France	MD Carole Azuar
P067	An automated method for quantifying syntactic complexity of spontaneous speech in Primary Progressive Aphasia	03. Neuropsychology	Galit	Agmon	United States	MD Naomi Nevler
P068	The interplay between pleasurable event generation and anhedonia and apathy in dementia - A preliminary study	03. Neuropsychology	Siobhan	Shaw	Australia	Siobhan Shaw
P069	A means to an end – Impaired social problem-solving in frontotemporal dementia	03. Neuropsychology	Muireann	Irish	Australia	Professor Muireann Irish
P070	A multimodal approach for the treatment of Primary Progressive Aphasia	03. Neuropsychology	Ilaria	Pagnoni	Italy	Ilaria Pagnoni
P071	Disentangling Neural Correlates of Reading the Mind in the Eyes and Executive Functions in Behavioral Variant Frontotemporal Dementia	03. Neuropsychology	Christopher	Weise	Germany	PD Dr. Christopher Weise
P072	Comparative diagnostic accuracy of MLSE, ACE-III, and DCQ for the diagnosis of primary progressive aphasia	03. Neuropsychology	Lucia	Fernandez Romero	Spain	Phd Student Lucia Fernandez Romero
P073	Use of the Aphasia Impact Questionnaire in individuals with primary progressive aphasia - preliminary results	03. Neuropsychology	Zsolt	Cséfalvay	Slovakia	Prof. Ph.D. Zsolt Cséfalvay
P075	A common marker of emotion recognition dysfunction in the FTL spectrum of disorders	03. Neuropsychology	Elisa	Canu	Italy	PhD Elisa Canu
P076	Introducing a new eye tracking task for social cognition in FTD	03. Neuropsychology	Liset	De Boer	Nederland	Liset De Boer
P077	Affective and cognitive theory of mind and associated brain functional alterations in patients with PPA	03. Neuropsychology	Chiara	Tripodi	United States	Chiara Tripodi
P078	Social functioning during lifetime influences the extent of behavioural decline in frontotemporal lobar degeneration	03. Neuropsychology	Monica	Consonni	Italy	Phd Monica Consonni
P079	Apathy in FTL-disorders: living in a world of "close enough"	03. Neuropsychology	Rebecca	Williams	United Kingdom	Miss Rebecca Williams
P080	Task-based indices of neurocognitive mechanisms underlying apathy in neurodegenerative dementias: findings from FTD, LBD, and AD	03. Neuropsychology	Rubina	Malik	Canada	Dr. Rubina Malik

P082	Update on the current state of speech and language testing in Alzheimers disease	03. Neuropsychology	Adam	Vogel	Australia	Professor Adam Vogel
P083	The utility of Speech and language Analytics for screening Alzheimer's disease and Schizophrenia	03. Neuropsychology	Adam	Vogel	Australia	Professor Adam Vogel
P084	Loss of word concreteness as an organisational principle of the semantic network in PPA SV	03. Neuropsychology	Rik	Vandenberghe	Belgium	Prof Rik Vandenberghe
P085	The Cambridge Questionnaire for Apathy and Impulsivity Traits (CamQUAIT): a novel assessment tool for FTLD	03. Neuropsychology	Rebecca	Williams	United Kingdom	Miss Rebecca Williams
P086	High impatience for reward in behavioral variant frontotemporal dementia is related to core behavioral symptoms and to medial pulvinar atrophy	03. Neuropsychology	Valérie	Godefroy	France	PhD Valérie Godefroy
P087	Exploring language functioning differences in behavioral variant frontotemporal degeneration and primary psychiatric disorders	03. Neuropsychology	Agnes	Deneve	France	Agnes Deneve
P088	It's all about how it's said: investigation of expressive prosody in FTLD & AD	03. Neuropsychology	Agnes	Deneve	France	Agnes Deneve
P089	Neuropsychological patterns in DSM-5 mild and major NCD warrant new approaches in conceptualizing dementia syndromes	03. Neuropsychology	Fabiola	Boehm	Germany	Fabiola Boehm
P090	The Dutch Mini-Linguistic State Examination (MLSE-NL): Preliminary Findings in Primary Apraxia of Speech (PAOS)	03. Neuropsychology	Rosie	Coppieters	Belgium	Rosie Coppieters
P091	Neuropsychological assessment in differentiating between behavioral variant frontotemporal dementia and Alzheimer's disease: a follow-up study	03. Neuropsychology	Noora-Maria	Suhonen	Finland	PhD Noora-Maria Suhonen
P092	Impaired Aversion to Harming Others During Moral Decision-Making correlates with antisocial behaviors in bvFTD Patients	03. Neuropsychology	Ryan	Darby	United States	Md Ryan Darby
P093	Can performance on a picture description task differentiate the nonfluent/agrammatic and logopenic variants of primary progressive aphasia?: Evidence from Catalan-Spanish bilinguals	07. Diversity	Stephanie	Grasso	United States	PhD Stephanie Grasso
P094	Spanish language and Costa Rican cultural adaptation of the ALLFTD genetic counseling protocol	07. Diversity	Sylvia	Joseph-Hernandez	Costa Rica	Md, Msc Sylvia Joseph-Hernandez
P095	Informant effect on the CDR® plus NACC FTLD SB scores in behavioural-variant Frontotemporal dementia	07. Diversity	Juan-camilo	Vargas-gonzalez	Canada	Dr. Juan-camilo Vargas-gonzalez
P096	Raising global awareness of frontotemporal dementia: The rise of World FTD United	07. Diversity	Sharon	Denny	United States	Tracey Wardill
P097	Digital neurorehabilitation in people with dementia	08. Clinical trials	Aygun	Badalova	United Kingdom	Phd Candidate Aygun Badalova
P098	Perceived FTD Risk and Clinical Trial Perspectives	08. Clinical trials	Shana	Dodge	United States	Dr. Shana Dodge
P099	The Progranulin Information Navigator: A Tool to Support GRN-FTD Clinical Trial Recruitment	08. Clinical trials	Laura	Mitic	United States	Laura Mitic
P100	Long-term Effect of Transcranial Magnetic Stimulation in Primary Progressive Aphasia (RECONNECT-PPA): study protocol for a Randomized, Double-Blind Clinical Trial	08. Clinical trials	Lucia	Fernandez Romero	Spain	Phd Student Lucia Fernandez Romero
P101	Efficient clinical trial design for symptoms of FTD: Lessons learned from FOXY	08. Clinical trials	Kristy	Coleman	Canada	Kristy Coleman
P102	FOXY - A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia	08. Clinical trials	Kristy	Coleman	Canada	Kristy Coleman

P103	Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS).	08. Clinical trials	Rob	Durcan	United Kingdom	Dr Rob Durcan
P104	A phase 2 placebo controlled randomised controlled trial of sodium selenate as a disease modifying treatment for progressive supranuclear palsy	08. Clinical trials	Lucy	Vivash	Australia	Dr Lucy Vivash
P105	ASPIRE-FTD: A Phase 1/2 Clinical Trial to Evaluate AVB-101 in FTD with GRN mutations (FTD-GRN)	08. Clinical trials	Jane	Chan	United Kingdom	Jane Chan
P106	Veri-T: a Phase 1, randomized, placebo-controlled trial of Verdiperstat in svPPA: an interim update	08. Clinical trials	Peter	Ljubekov	United States	MD Peter Ljubekov
P107	The Early Detection of Frontotemporal Dementia and Motor Neuron Disease (EDoF) Project	08. Clinical trials	Kerala	Adams-Carr	United Kingdom	Dr Kerala Adams-Carr
P108	Telerehabilitation and home-based transcranial direct current stimulation for people with primary progressive aphasia	08. Clinical trials	Anna	Rysop	Rusina	Anna Rysop
P109	Pipeline to Participation: A Family-led Effort to Understand Perspectives among FTD-GRN Families	08. Clinical trials	Wanda	Smith	United States	California Senior Legislature Wanda Smith
P110	Informants (Study Partners) in presymptomatic FTD Research: Highlighting uncharacterized and uncommunicated potential risks	08. Clinical trials	Jean	Swidler	United States	Jean Swidler
P111	Caregiver Preferences for Peer-to-Peer Support in the Connect2Caregiver Research Study Cohort	08. Clinical trials	Leah	Forsberg	United States	Phd Leah Forsberg
P112	Biomarker analysis from PROCLAIM, a Gene Therapy Trial for Frontotemporal Dementia Patients with GRN Mutations	08. Clinical trials	Sebastian	Boland	United States	Vice President - Clinical Development Olga Uspenskaya
P113	Results of Low-Dose Lithium Clinical Trial for Treatment of Behavioral Symptoms in FTD	08. Clinical trials	Colin	Stein	United States	Masood Manoochehri
P114	GENFI motor scores correlate with objective motor measures	08. Clinical trials	Justin	Kwan	United States	Md Justin Kwan
P115	Dopaminergic Therapy for Frontotemporal Dementia Patients: preliminary results from a phase 2 multi-site, Randomized Clinical Trial	08. Clinical trials	Giacomo	Koch	Italy	Prof Giacomo Koch
P116	Palmitoylethanolamide Combined with Luteoline in Frontotemporal Dementia patients (PEA-FTD): A phase 2 Randomized Clinical Trial	08. Clinical trials	Giacomo	Koch	Italy	Martina Assogna
P117	Early dysregulation of microglia-secreted AIM in frontotemporal dementia caused by CHMP2B mutation	02a. Fluid biomarkers	Anders	Toft	Denmark	Post Doc Anders Toft
P130	Neurodevelopmental brain reserve in genetic frontotemporal dementia	02b. Imaging biomarkers	Luke	Harper	Sweden	Dr Luke Harper
P131	Neurodevelopmental implications of genetic FTD revealed through intracranial volume differences in mutation carriers and non-carriers	02b. Imaging biomarkers	Isis	So	Canada	Ms. Isis So
P132	A Functional Magnetic Resonance Imaging Study of Musical Object Processing in Dementia	02b. Imaging biomarkers	Lucy	Core	United Kingdom	Lucy Core
P133	Altered empathy processing in frontotemporal dementia A task-based fMRI study	02b. Imaging biomarkers	Olof	Lindberg	Sweden	Phd Olof Lindberg
P134	Visual rating scales of atrophy to differentiate Frontotemporal dementia from Primary psychiatric disorder: DIPPA study	02b. Imaging biomarkers	Giorgio Giulio	Fumagalli	Italy	M.D. Giorgio Giulio Fumagalli
P135	Unraveling amyloid and tau contributions to neurodegeneration in CBS: a multimodal PET study	02b. Imaging biomarkers	Alma	Ghirelli	Italy	Dr Alma Ghirelli

P136	Investigating Neuroinflammation in Frontotemporal Lobar Degeneration using Ultra-High Field MRI	02b. Imaging biomarkers	Fieke	Prinse	Nederland	Fieke Prinse
P137	Sulcal morphology analysis to differentiate behavioral variant frontotemporal dementia from psychiatric disorders	02b. Imaging biomarkers	Giorgio Giulio	Fumagalli	Italy	M.D. Giorgio Giulio Fumagalli
P138	TSPO PET predicts volumetric MRI changes in Progressive Supranuclear Palsy.	02b. Imaging biomarkers	Noah L.	Shapiro	United Kingdom	Noah L. Shapiro
P139	Structural brain alterations in patients with criminal behavior in frontotemporal dementia	02b. Imaging biomarkers	Matthias	Schroeter	Germany	Matthias L Schroeter
P140	Longitudinal progression of subcortical structural damage in amyotrophic lateral sclerosis	02b. Imaging biomarkers	Edoardo Gioele	Spinelli	Italy	Edoardo Gioele Spinelli
P141	Distinctive longitudinal cortical atrophy progression patterns characterize clinical variants of the frontotemporal dementia continuum	02b. Imaging biomarkers	Edoardo Gioele	Spinelli	Italy	Edoardo Gioele Spinelli
P142	A pipeline for comparing and combining TSPO-PET tracers: Progressive Supranuclear Palsy as an exemplar disorder.	02b. Imaging biomarkers	Harry	Crook	United States	Mr Harry Crook
P143	Neuroimaging meta-analyses reveal the convergence of interoception, emotion, and social cognition across neurodegenerative diseases	02b. Imaging biomarkers	Jessica	Hazelton	Chile	Dr Jessica Hazelton
P144	Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43 PET tracer	02b. Imaging biomarkers	Viktoriiia	Gerasymchuk	Switzerland	MD, PhD Viktoriiia Gerasymchuk
P145	Spatial and Temporal Progression of Right Hemisphere Atrophy in Primary Progressive Aphasia due to TDP-43 Type C Pathology	02b. Imaging biomarkers	Jane	Stocks	United States	Dr. Jane Stocks
P146	Structure-function decoupling in genetic frontotemporal dementia	02b. Imaging biomarkers	Kamen	Tsvetanov	United Kingdom	Dr Kamen Tsvetanov
P147	Neural mechanisms underlying memory deficits in premanifest C9orf72-repeat expansions	02b. Imaging biomarkers	Jiaze	Sun	Belgium	Jiaze Sun
P148	Unravelling White Matter Integrity Changes in Genetic Frontotemporal Dementia	02b. Imaging biomarkers	Ninon	Peysson	France	Ninon Peysson
P149	Cortical thickness and volume in genetic frontotemporal dementia: a cross-sectional and longitudinal study	02b. Imaging biomarkers	Giulia	Campana	France	Physician Trainee Giulia Campana
P150	Accuracy of FDG-PET to differentiate sporadic bvFTD from late onset psychiatric disorders	02b. Imaging biomarkers	Ishana	Rue	Canada	Ms Ishana Rue
P151	Quantifying progression in early and late-onset behavioral variant frontotemporal dementia with structural neuroimaging	02b. Imaging biomarkers	Fabiola	Boehm	Germany	Fabiola Boehm
P152	Distinguishing Frontotemporal Lobar Degeneration Tau from TDP-43 using white matter microstructure	02b. Imaging biomarkers	Hamsanandini	Radhakrishnan	United States	Dr. Hamsanandini Radhakrishnan
P153	Differential Involvement of the Dorsal and Ventral Temporo-Frontal Extreme Capsule Fasciculus in Primary Progressive Aphasia	02b. Imaging biomarkers	Kyriaki	Neophytou	United States	Kyriaki Neophytou
P154	Fibre-specific changes in amygdala-associated white matter tracts in frontotemporal dementia	02b. Imaging biomarkers	Mengjie	Huang	Australia	Ms Mengjie Huang
P155	Transdiagnostic Network Localization of Social, Language, and Motor Symptoms in Frontotemporal Lobar Degeneration	02b. Imaging biomarkers	Ryan	Darby	United States	Md Ryan Darby
P156	Distinct brain imaging trajectories of motor speech disturbances in nonfluent progressive aphasia syndromes	02b. Imaging biomarkers	Halle	Quang	Viet Nam	Dr Halle Quang

P157	Lower amygdala volume correlates with TDP-43 load in limbic-predominant age-related TDP-43 encephalopathy (LATE).	02b. Imaging biomarkers	Alex	Wesseling	Netherlands	Alex Wesseling
P158	Common Associations of Transcranial Magnetic Stimulation (TMS) Parameters and Behavioral Symptoms in Different Neurocognitive diseases	02b. Imaging biomarkers	Laura	Säisänen	Finland	Laura Säisänen
P159	Unveiling Primary Progressive Aphasia Progression: A Longitudinal Study on Grey and White Matter Degeneration	02b. Imaging biomarkers	Runtian	Miao	United States	Runtian Miao
P160	Tau and TDP-43 pathologies show distinct patterns of neurodegeneration in frontotemporal dementia	02b. Imaging biomarkers	Sophie	Matis	Australia	Sophie Matis
P161	Semantic blurring and atrophy progression in FTLTDP-C pathology	02b. Imaging biomarkers	Elena	Barbieri	United States	Dr. Elena Barbieri
P162	Regional cerebral blood flow in vivo is associated with GFAP at autopsy in FTLD-tau	02b. Imaging biomarkers	Christopher	Olm	United States	Dr. Christopher Olm
P163	Public release of imaging data from ALLFTD and ARTFL-LEFFTDS	02b. Imaging biomarkers	Christopher	Schwarz	United States	Dr. Christopher Schwarz
P164	Medial temporal lobe subregional atrophy patterns in presymptomatic and symptomatic genetic frontotemporal lobar degeneration	02b. Imaging biomarkers	Leslie	Gaynor	United States	Dr. Leslie Gaynor
P165	Effects of De-Facing with mri_reface on the Statistical Power of Brain Imaging Biomarkers of PSP	02b. Imaging biomarkers	Christopher	Schwarz	United States	Dr. Christopher Schwarz
P166	Selective cytoarchitectonic network disruption in semantic dementia	02b. Imaging biomarkers	Belen	Pascual	United States	Kaitlee Ornelas
P167	Post-Mortem Validation of Translocator Protein (TSPO) as a PET Neuroinflammatory Biomarker in Progressive Supranuclear Palsy	02b. Imaging biomarkers	Sasvi	Wijesinghe	United Kingdom	Miss Sasvi Wijesinghe
P168	Post-mortem validation of synaptic biomarker UCB-J PET in progressive supranuclear palsy	02b. Imaging biomarkers	George	Nolan	United Kingdom	Mr George Nolan
P169	Frontotemporal Dementia and Alzheimer Diagnosis using a Novel Resting-State Scalp EEG Marker	02b. Imaging biomarkers	Luis	Sanchez	United States	Luis Sanchez
P170	Early Primary Progressive Aphasia Atrophy Asymmetry as a Predictor of Neuropathological Diagnosis	02b. Imaging biomarkers	Sarah	Simon	United States	Dr. Elena Barbieri
P171	Functional Connectivity in Genetic Frontotemporal Dementia: a GENFI study	02b. Imaging biomarkers	Arabella	Bouzigues	France	Miss Arabella Bouzigues
P172	NEUROANATOMY OF BEHAVIORAL CHANGES IN SEMANTIC VARIANT OF PRIMARY PROGRESSIVE APHASIA	02b. Imaging biomarkers	Yulia	Shpilyukova	Russian Federation	Dr Yulia Shpilyukova
P173	Longitudinal analysis of multi-center harmonized DTI-MRI data in genetic FTD.	02b. Imaging biomarkers	Tine	Swartenbroekx	Netherlands	Tine Swartenbroekx
P174	Deep Learning-Based MRI Analysis for Differential Diagnosis in Neuropsychiatric Presentations: A Clinical Cohort Study	02b. Imaging biomarkers	Matthew	Kang	Australia	Dr Matthew Kang
P175	Neuropsychological dysfunction differentially relates to desegregation of brain networks in behavioral variant frontotemporal dementia	02b. Imaging biomarkers	Melanie	Matyi	United States	PhD Melanie Matyi
P176	Latent atrophy factors in Primary Progressive Aphasia related to Alzheimer's pathology and linguistic features across different cultural settings.	02b. Imaging biomarkers	Ismael	Calandri	Netherlands	Ismael Calandri
P177	Free-water Diffusion and Quantitative T1 mapping in FTLD	02b. Imaging biomarkers	Vishaal	Sumra	Canada	Doctoral Student Vishaal Sumra

P178	Identifying synaptic manifold effects of frontotemporal lobar degeneration	02b. Imaging biomarkers	Manfred	Kitzbichler	United Kingdom	Dr Manfred Kitzbichler
P179	Longitudinal functional connectivity changes identify asymptomatic MAPT mutation carriers with signs of accelerated disease progression	02b. Imaging biomarkers	Youjin	Jung	United States	PhD Youjin Jung
P180	Short and long-distance neural alterations in semantic dementia using advanced diffusion MRI techniques	02b. Imaging biomarkers	Maria Luisa	Mandelli	United States	Maria Luisa Mandelli
P181	Sleep-wake Characteristics and associated Atrophy in Frontotemporal Dementia	02b. Imaging biomarkers	Ciaran	Considine	United States	Associate Professor of Neurology Ciaran Considine
P182	Reduced white matter integrity in right uncinate fasciculus predicts rule-breaking behavior in behavioral-variant frontotemporal dementia	02b. Imaging biomarkers	Jayden	Lee	United States	Dr. Jayden J. Lee
P183	Brain Age Gap Improves Predictions of Cognitive Scores Changes in Genetic Frontotemporal Dementia	02b. Imaging biomarkers	Reza	Rajabli	Canada	Mahdie Soltaninejad
P184	Different functional connectivity disruption patterns between logopenic variant PPA and Alzheimer's disease	02b. Imaging biomarkers	Michele	Masson-Trottier	United States	Michele Masson-Trottier
P185	Cerebral blood flow deficits and longitudinal decline in presymptomatic and symptomatic frontotemporal lobar degeneration	02b. Imaging biomarkers	Amy	Wolf	United States	Amy Wolf
P186	Cognitive and behavioural tools to differentiate behavioural variant frontotemporal dementia from other conditions.	03. Neuropsychology	Joshua	Flavell	Australia	Dr Joshua Flavell
P187	Effect of Semantic Feature Analysis (SFA) rehabilitation in patients with primary progressive semantic aphasia: a SCED study	03. Neuropsychology	Sarah	Maso	France	Sarah Maso
P188	Diagnostic utility of the Social Behavior Observer Checklist in neurodegenerative assessment: Insights from Spain's biomarker-enriched cohort	03. Neuropsychology	Judit	Selma-Gonzalez	Spain	Phd student Judit Selma-Gonzalez
P189	Measuring the sense of agency in patients with apathy: evidence from the intentional binding effect in FTD, AD and LBD	03. Neuropsychology	Rubina	Malik	Canada	Dr. Rubina Malik
P190	Deep phenotyping of primary progressive aphasia to improve diagnosis	03. Neuropsychology	Aurore	Mahut-dubos	France	PhD student Aurore Mahut-dubos
P191	Longitudinal language changes in primary progressive aphasia	03. Neuropsychology	Aurore	Mahut-dubos	France	PhD student Aurore Mahut-dubos
P192	A novel observational task reveals behavioural patterns in unfamiliar environments associated with apathy in dementia	03. Neuropsychology	James	Carrick	Australia	Dr Grace Wei
P193	Clinical performance of socio-emotional sensitivity and empathy questionnaires in the early diagnosis of the frontotemporal dementia variants	03. Neuropsychology	Andrea	Panzavolta	Italy	Dr. Andrea Panzavolta
P194	Preliminary Comparison of Outcome Measures Between FTD-specific Cognitive Testing Apps (ALLFTD App vs Ignite App)	03. Neuropsychology	Eva	Larsen	United Kingdom	Eva Larsen
P195	Association between amygdala atrophy and social cognition in behavioural variant frontotemporal dementia and semantic dementia	03. Neuropsychology	Mengjie	Huang	Australia	Ms Mengjie Huang
P196	German Version of the Mini Social & Emotional Assessment: Clinical Utility and Structural Neural Correlates	03. Neuropsychology	Cem	Dogdu	Germany	Cem Dogdu
P197	Profiles and Predictors of Social Functioning in Frontotemporal Dementia and Alzheimer's Disease	03. Neuropsychology	Grace	Wei	Australia	Dr Grace Wei
P198	Buccofacial apraxia in primary progressive aphasia	03. Neuropsychology	Keisuke	Morihara	Japan	Dr Keisuke Morihara

P199	VALIDATION OF THE DYNAMIC AFFECT RECOGNITION TEST: A BRIEF, VIDEO-BASED EMOTION IDENTIFICATION TASK	03. Neuropsychology	Hulya	Ulugut	United States	M.d., Phd Hulya Ulugut
P200	COMPARING THE VALUE OF DYNAMIC VS. STATIC-IMAGE-BASED TESTS OF EMOTION RECOGNITION FOR FRONTOTEMPORAL DEMENTIA SUBTYPING	03. Neuropsychology	Hulya	Ulugut	United States	M.d., Phd Hulya Ulugut
P201	Inhibitory Control Deficits in Syndromes Associated with Frontotemporal Lobar Degeneration	03. Neuropsychology	Michelle	Naessens	United Kingdom	Michelle Naessens
P202	Hippocampal Vulnerability and Cognitive Impact of TDP-43 in SuperAgers	03. Neuropsychology	Grace	Minogue	United States	Grace Minogue
P203	Daily Emotional Experience is Elevated in Asymptomatic FTD Gene Carriers and Related to Larger Volume in Emotion-Relevant Brain Regions	03. Neuropsychology	Ashlin	Roy	United States	Ashlin Roy
P204	Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD)	03. Neuropsychology	Eden	Barragan	United States	PhD Eden Barragan
P205	Education mediates the association between motor and frontotemporal-spectrum involvement in non-demented ALS patients	03. Neuropsychology	Edoardo Nicolò	Aiello	Italy	Dr. Edoardo Nicolò Aiello
P206	Cognitive Profiles in Dutch Senior Psychiatric Patients: The Predictive Role of Diagnosis and the Association of Gender and Age with Cognitive Domains	03. Neuropsychology	Ezgi	Argün	Netherlands	Ezgi Argün
P207	The auditory phenotype of behavioural variant and right temporal variant frontotemporal dementia	03. Neuropsychology	Benjamin	Levett	United Kingdom	PhD Student Benjamin Levett
P208	Speech comprehension in reverberant virtual soundscapes in logopenic aphasia and Alzheimer's disease	03. Neuropsychology	Benjamin	Levett	United Kingdom	PhD Student Benjamin Levett
P209	The Social Cognition Workgroup of the Neuropsychiatric International Consortium Frontotemporal Dementia (scNIC-FTD)	03. Neuropsychology	Jan	Van Den Stock	Belgium	Professor Jan Van Den Stock
P210	Impairments in Daily Living differ across Frontotemporal Dementia Subtypes irrespective of global cognitive impairment	03. Neuropsychology	Emma	Weltings	Netherlands	Drs. Emma Weltings
P211	Early cognitive deficits in families with the C9orf72 expansion detected by the Ignite app	03. Neuropsychology	Phoebe	Foster	United Kingdom	Miss Phoebe Foster
P212	Semi-Automated Quantitative Speech Markers in Genetic Frontotemporal Dementia	03. Neuropsychology	Arabella	Bouzigues	France	Miss Arabella Bouzigues
P214	Knowledge of social norms deficits and their underlying mechanisms in Alzheimer's disease and behavioral variant frontotemporal dementia	03. Neuropsychology	Thomas	Carrier	Canada	PhD student Thomas Carrier
P215	The Impact of Sex on Clinical Profiles in Behavioural Variant of Frontotemporal Dementia	03. Neuropsychology	Parsa	Afrooz	Canada	Parsa Afrooz
P216	Language impairment associated with progression in progressive supranuclear palsy	03. Neuropsychology	Indira Ruth	Garcia Cordero	Canada	PhD Indira Ruth Garcia Cordero
P217	The capacity of neuropsychological assessment to predict regional brain metabolism in patients with AD and bvFTD	03. Neuropsychology	Lucia	Fernandez Romero	Spain	Phd Student Lucia Fernandez Romero
P218	Exploring Cognitive and Behavioral Profiles of Patients with Frontotemporal Dementia Using K-Means Clustering	03. Neuropsychology	Marie	Söntgerath	Germany	Marie Söntgerath
P219	Types of dyslexia in Primary Progressive Aphasia	03. Neuropsychology	Yuval Z.	Katz	Israel	Mr. Yuval Z. Katz
P220	Preliminary data of empathy impairments in bvAD using the French adaptation of the Multifaceted empathy test	03. Neuropsychology	Elizabeth	Poulin	Canada	Elizabeth Poulin

P221	Types of lexical retrieval and comprehension deficits in primary progressive aphasia	03. Neuropsychology	Yuval Z.	Katz	Israel	Ophir Keret
P222	A Mechanistic study of Eating Behavior In Frontotemporal dementia	03. Neuropsychology	Laura	Van Hove	Belgium	Laura Van Hove
P223	Long-term, Home-based tDCS Coupled with Computerized Cognitive Training in Frontotemporal Dementia: A Case Report	03. Neuropsychology	Donna	Tippett	United States	Ms Donna Tippett
P224	Socioemotional-Cognitive Dysfunction but not Executive Dysfunction relates to Social-Norm Transgression in Behavioral Variant Frontotemporal Dementia	03. Neuropsychology	Siyi	Wang	United States	Siyi Wang
P225	Evaluation of sentence production in Spanish speakers with primary progressive aphasia	03. Neuropsychology	Miguel Angel	Santos	Spain	Dr. Miguel Angel Santos
P226	Impaired semantic word learning in primary progressive aphasia	03. Neuropsychology	Miguel Angel	Santos	Spain	Dr. Miguel Angel Santos
P227	TECHNOLOGY-ASSISTED SEMANTIC THERAPY: EVIDENCE OF DAY TO DAY COMMUNICATION	03. Neuropsychology	Marion	Castéra	France	PhD Student, Speech and Language Pathologist Marion Castéra
P228	Neural Correlates of Anosognosia in Neurodegenerative Disorders	04. Neuropsychiatry	Serap	Özlü	Turkey	Serap Özlü
P229	miRNA expression profile in symptomatic and asymptomatic genetic FTD	05. Genetics	Chiara	Fenoglio	Italy	Phd Chiara Fenoglio
P230	Single-nucleus multi-omics identifies shared and distinct pathways of Alzheimer's and Pick's disease	05. Genetics	Vivek	Swarup	United States	Dr. Vivek Swarup
P231	Brain asymmetry in FTD-GRN: Prediction disease onset and differentiation between two syndromes	05. Genetics	Sergi	Borrego Écija	Spain	Sergi Borrego Écija
P232	Reconsidering relationships between C9orf72 expansion profiles and clinical variability in the post southern-blot era.	05. Genetics	Mathieu	Barbier	France	Dr. Mathieu Barbier
P233	Clinicopathological phenotype of the p.P397S MAPT mutation	05. Genetics	Sergi	Borrego Écija	Spain	Inés Bartolomé
P234	Light The Way: Multinational Online Education, Counseling, and Testing Platform for Genetic ALS/FTD	05. Genetics	Paul	Wicks	United Kingdom	Dr Paul Wicks
P235	Genetics of Semantic Dementia: New Data from Monozygotic Twins and a Review of Genetic Cases	05. Genetics	Shalom	Henderson	United Kingdom	Shalom Henderson
P236	Increased Epigenetic Aging in Frontotemporal Dementia	05. Genetics	Naren	Ramesh	United States	Lianne M. Reus
P237	A Novel MAPT P301A Mutation Presenting as Early Onset Rapidly Progressive Frontotemporal Dementia	05. Genetics	Kiet	Hua	United States	Behavioral Neurology Training Program Fellow, MD, PhD Kiet Hua
P238	MAPT Families Fighting For A Future	05. Genetics	Linde	Jacobs	United States	Rn Linde Jacobs
P239	A novel missense GRN variant: uncovering pathogenicity using patient-derived induced pluripotent stem cells	05. Genetics	Anna	Chauveau	Switzerland	Anna Chauveau
P240	A Framework for Advancing Research through Genetic Data Stewardship	05. Genetics	Jalayne	Arias	United States	Associate Professor Jalayne Arias
P241	Semantic behavioral variant of frontotemporal dementia and semantic dementia associated with TARDBP mutation	05. Genetics	Giuseppe	Piga	Italy	Dr. Giuseppe Piga

P242	Atypical facial behaviors in patients with C9orf72 hexanucleotide repeat expansions have diffuse neural representations in primary motor cortex	05. Genetics	Fate	Noohi	United States	Fate Noohi
P243	A polygenic score for executive function correlates with differential rates of cognitive decline	05. Genetics	Nadia	Dehghani	United States	Dr Nadia Dehghani
P244	Gene specific effects on brain volume and cognition of TMEM106B in frontotemporal lobar degeneration	05. Genetics	Marijne	Vandebergh	Belgium	Marijne Vandebergh
P245	Genetic Contributions to Alzheimer's Disease and Frontotemporal Dementia in Admixed Latin American Populations	05. Genetics	Nick	Cochran	United States	Faculty Investigator Nick Cochran
P246	Effect of Genetic Mutation Status on Clinical Features in FTL-DTP Types A and B.	05. Genetics	Sean	Coulborn	United States	Dr Sean Coulborn
P247	C9orf72 repeat expansions increase risk for secondary symptom development in amyotrophic lateral sclerosis and behavioral-variant frontotemporal degeneration	05. Genetics	Barbara	Spencer	United States	Dr Barbara Spencer
P248	Rare tandem repeat expansions in FTL-DTP	05. Genetics	Wouter	De Coster	Belgium	Dr. Wouter De Coster
P249	Characterizing MAPT variation and expression in Pick's disease	05. Genetics	Nicole	Tamvaka	United States	Nicole Tamvaka
P250	Behavioral variant frontotemporal dementia and the DYSF gene: causal relationship or coincidence? A case report	05. Genetics	Thamires	Marx Da Silva Santos	Brazil	Dr Thamires Marx Da Silva Santos
P251	Genetic screening of ANXA11 in Korean patients with Frontotemporal dementia syndrome	05. Genetics	Sun Min	Lee	South Korea	Dr. Sun Min Lee
P252	TMEM106B modifies the effect of FTD mutations on brain volumes, serum NfL, and cognition in genetic FTD. A GENFI study	05. Genetics	Saira	Mirza	Canada	Mario Masellis
P253	Genetic variants in known genes in diverse Frontotemporal Dementia cohort, enriched for Caribbean Hispanic patients.	05. Genetics	Karen	Nuytemans	United States	Karen Nuytemans
P254	A novel CHMP2B splicing mutation is associated with familial FTL	05. Genetics	Sara	Rubio-Guerra	Spain	Sara Rubio-Guerra
P255	Screening for variants in CSF1R gene may help in identifying FTD mimics	05. Genetics	Andrea	Mastrangelo	Italy	Dr. Andrea Mastrangelo
P256	The role of GRN in unexplained FTL-DTP type A	05. Genetics	Elise	Coopman	Belgium	Elise Coopman
P257	An Epigenome Wide Association Study of Primary Age-Related Tauopathy	05. Genetics	Anil	Wadhvani	United States	Dr. Anil Wadhvani
P282	BARCELONA SCALE FOR BUCCOPHONATORY APRAXIA IN PRIMARY PROGRESSIVE APHASIA: A LONGITUDINAL CASE SERIES	06. Clinic	Núria	Montagut	Spain	Dr. Núria Montagut
P283	Epilepsy might be associated with the pathogenesis of FTD	06. Clinic	Annemari	Kilpeläinen	Finland	Md Annemari Kilpeläinen
P284	A patient with semantic behavioural variant frontotemporal dementia with obsessive compulsive disorder in the past	06. Clinic	Jacqueline	Mulder	Netherlands	Dr Jacqueline Mulder
P285	A Pupillometric Study of Musical Object Processing in Dementia	06. Clinic	Lucy	Core	United Kingdom	Lucy Core
P286	Defining Repetitive Behaviors in Frontotemporal Dementia	06. Clinic	Miguel	Restrepo	Colombia	Md Miguel Restrepo

P287	Erotomania in Frontotemporal Dementia	06. Clinic	Miguel	Restrepo	Colombia	Md Miguel Restrepo
P288	Clinical differentiation of rtvFTD from psychiatric disease (a case study)	06. Clinic	Sigfried	Schouws	Netherlands	Phd Sigfried Schouws
P289	Right temporal variant FTD in association with amyotrophic lateral sclerosis: A case series	06. Clinic	Johannes	Prudlo	Germany	Johannes Prudlo
P290	Perceived life and loneliness of bvFTD patients showed decrease already 5-10 years before diagnosis	06. Clinic	Kalle	Aho	Finland	PhD Student Kalle Aho
P291	Prevalence and Features of Misdiagnosis of Primary Psychiatric Disorders in Patients Diagnosed with bvFTD	06. Clinic	Elvis-Raymond	Mukwikwi	Canada	Dr. Elvis-Raymond Mukwikwi
P292	Frontotemporal dementia and the roles of left and right temporal lobes in cognition and behaviour	06. Clinic	Jennifer	Thompson	United Kingdom	Dr Jennifer Thompson
P293	Validity Analysis of Proposed Diagnostic Criteria for Right Temporal Variant of Frontotemporal Dementia in South Korea	06. Clinic	Na-yeon	Jung	South Korea	Professor Eun-Joo Kim
P294	Neuropsychiatric Symptoms Cluster and Fluctuate Over Time in Behavioral Variant Frontotemporal Dementia	06. Clinic	Christopher	Morrow	United States	Dr. Christopher Morrow
P295	Caregiver Burden Clusters in Frontotemporal Dementia: Caregiver Experiences and the Interactions with Psychiatric States and Disability	06. Clinic	Christopher	Morrow	United States	Dr. Christopher Morrow
P296	Testing Feasibility of a Remote Hearing Test in Patients with Suspected Frontotemporal Lobar Degeneration	06. Clinic	Rene	Utianski	United States	Dr Rene Utianski
P297	Comprehension difficulties are associated with higher agitation burden in patients participating in the ALLFTD Study	06. Clinic	Juan-camilo	Vargas-gonzalez	Canada	Dr. Juan-camilo Vargas-gonzalez
P298	Latent Class Growth Analysis of Neuropsychiatric Symptoms in Frontotemporal Dementia Mutation Carriers	06. Clinic	Imogene	Scott	Canada	Dr Imogene Scott
P299	Factors associated with true- and false-positive diagnosis of behavioural variant frontotemporal dementia in 100 consecutive referrals from specialist physicians.	06. Clinic	Joshua	Flavell	Australia	Dr Joshua Flavell
P300	Assessing criminal risk behaviours in frontotemporal dementia syndromes and Alzheimer's disease	06. Clinic	Pratiksha	Kumar	Australia	Olivier Piguet
P301	Depressive symptoms in early-stage frontotemporal dementia: Prodrome or major depression?	06. Clinic	Satoshi	Ueda	Japan	Dr. Satoshi Ueda
P302	Neurological, cognitive and psychiatric features of PPA: a naturalistic study of a large cohort over 10 years	06. Clinic	Robert	Laforce	Canada	Neurologist Robert Laforce
P303	Utility of MDS-PSP diagnostic criteria in recognising frontal cognitive-behavioural features in Progressive Supranuclear Palsy	06. Clinic	Jessica	Haigh	United Kingdom	Miss Jessica Haigh
P304	Multidomain Impairment Rating (MIR) Scale Reliability Study in ALLFTD Participants	06. Clinic	Toji	Miyagawa	United States	Md, Phd Toji Miyagawa
P305	Self-reported dysphagia symptoms in patients with primary progressive apraxia of speech	06. Clinic	Gabriela	Meade	United States	Dr. Gabriela Meade
P306	Progression of motor speech function in patients with primary progressive apraxia of speech	06. Clinic	Gabriela	Meade	United States	Dr. Gabriela Meade
P307	Disease-specific changes in neurotransmitter profiles in frontotemporal dementia: implications for cognitive and behavioural symptoms	06. Clinic	Tao	Chen	Australia	Dr Tao Chen

P308	High Rates of Diagnostic Discordance and Co-pathology: Insights into PSP from the NACC Dataset	06. Clinic	Tanav	Popli	United States	Dr. Tanav Popli
P309	Examining criminal risk behaviours and their underlying neural correlates in frontotemporal dementia	06. Clinic	Ramon	Landin-Romero	Australia	Lena Szabo
P310	Progressive Oral Apraxia of Reading	06. Clinic	Elena	Barbieri	United States	Dr. Elena Barbieri
P311	Longitudinal variability in resting heart rate as a marker of early autonomic dysfunction in manifest familial FTD	06. Clinic	Emma	Rhodes	United States	Dr. Emma Rhodes
P312	UNDERSTANDING UNIQUE SYMPTOMS IN SEMANTIC BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA: ROLE OF ALTERED INTRINSIC FUNCTIONAL CONNECTIVITY	06. Clinic	Hulya	Ulugut	United States	M.d., Phd Hulya Ulugut
P314	C9orf72 repeat expansion carriers in the Northern Finland Birth Cohorts: Investigation of early cognitive manifestations	06. Clinic	Nora	Linna	Finland	MD Nora Linna
P315	Carer perspectives enable accurate diagnosis of syndromes associated with frontotemporal lobar degeneration	06. Clinic	Alexander	Murley	United Kingdom	Dr Alexander Murley
P316	Post-fall cognitive dysfunction and neuropsychiatric issues in neurodegenerative disease patients and significant differences in Frontotemporal Dementia	06. Clinic	Goldin	Joghataie	Canada	Goldin Joghataie
P317	Relationships between movement disorder at presentation and clinical profile in frontotemporal dementia and atypical parkinsonism	06. Clinic	Manisha	Narasimhan	Australia	
P318	Analyses of Quality of Life in Frontotemporal Lobar Degeneration: Findings from the ALLFTD Consortium	06. Clinic	Kevin	Nelson	United States	Kevin Nelson
P319	Speech and language intervention in primary progressive aphasia: an European Rare Disease Network (ERN-RND) survey	06. Clinic	Robert	Rusina	Czech Republic	Robert Rusina
P320	PHARMACOLOGICAL TREATMENT OF BEHAVIORAL SYMPTOMS IN FRONTOTEMPORAL DEMENTIA; PREFERRED CLINICAL PRACTICE	06. Clinic	Dirk	van Paassen	Nederland	Msc/ma Dirk van Paassen
P321	Symptomatic conversion in a case of sporadic Frontotemporal Dementia: a retrospective, longitudinal neuroimaging study	06. Clinic	Luc	Hartog	Netherlands	MSc Luc Hartog
P322	"I'M SENDING YOU HEALING MAGIC": HEIGHTENED FEELINGS OF CONNECTEDNESS IN SEMANTIC BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA	06. Clinic	Anna	Gilioli	United States	Phd Anna Gilioli
P323	Apraxia phenotypes and frontotemporal lobar degeneration	06. Clinic	Tobias	Langheinrich	United Kingdom	Dr Tobias Langheinrich
P324	C9orf72-bvFTD despite little or no TDP-43 pathology in relevant brain regions	06. Clinic	Sevinc	Jakab	United States	Postdoc Scholar Sevinc Jakab
P325	Heralding phenotypes of behavioral variant frontotemporal dementia: a retrospective study	06. Clinic	Simon	Lecerf	France	Dr Simon Lecerf
P326	ALLFTD: Longitudinal Characterization of Frontotemporal Lobar Degeneration (FTLD) Disease in a North American Cohort	06. Clinic	Hilary	Heuer	United States	Dr. Hilary Heuer
P327	Factors associated with consultation and diagnostic delays in frontotemporal dementia	06. Clinic	Simon	Lecerf	France	Dr Simon Lecerf
P328	Descriptive themes of dementia related sexual behavior changes: A transdiagnostic approach	06. Clinic	Manizhe	Eslami-Amirabadi	United States	Manizhe Eslami-Amirabadi
P329	APHASIC BINARY REVERSALS AS A NOVEL BIOMARKER OF NFVPPA AND CORTICOBASAL DEGENERATION PATHOLOGY	06. Clinic	Zachary	Miller	United States	Dr. Zachary Miller

P330	Evaluation of a brief smartphone cognitive task for predicting disease severity in frontotemporal dementia.	06. Clinic	Jack	Taylor	United States	Jack Taylor
P331	Frontotemporal Dementia: Presence of Agitation and Implications to Function	06. Clinic	Celine	Sakran	Canada	Miss Celine Sakran
P332	Pre-clinical development of AVB-101, an AAV gene therapy treatment for frontotemporal dementia with progranulin mutations	10. Translational research	Carlos	Miranda	United Kingdom	Dr. Carlos Miranda
P333	Utilizing neuroimaging-based artificial intelligence for frontotemporal lobar degeneration diagnosis: A systematic review and meta-analysis	10. Translational research	Qiong	Wu	Germany	Dr. Qiong Wu
P334	Disentangling alterations in the bulk transcriptome from the brain of FTD cases at single-cell resolution	10. Translational research	Oriol	Dols Icardo	España	Phd Oriol Dols Icardo
P335	Exploring the effects of a multimodal approach for Primary Progressive Aphasia treatment on biological markers	10. Translational research	Sonia	Bellini	Italy	Dr. Sonia Bellini
P336	Differential Diagnosis of Dementia Syndromes using Multimodal Deep Learning	10. Translational research	Eóin	Molloy	Germany	Dr Eóin Molloy
P337	Identification of genetic and molecular hallmarks related to Frontotemporal Lobar Degeneration	10. Translational research	Antonio	Longobardi	Italy	Dr. Antonio Longobardi
P338	Deep transcriptomic profiling of the human frontal cortex in C9orf72-related FTD and ALS	10. Translational research	Evan	Udine	United States	Evan Udine
P339	Early dysregulation of Gpnmb-mediated peripheral inflammatory responses in Progranulin deficiency	10. Translational research	Malu	Tansey	United States	Professor Malu Tansey
P340	MRI-based Classifier to Identify Close-to-onset Cases in C9orf72 Genetic Frontotemporal Dementia	10. Translational research	Mahdie	Soltaninejad	Canada	Phd Candidate Mahdie Soltaninejad
P341	Self-supervised speech representation learning creates a powerful classifier for frontotemporal dementia spectrum disorders	10. Translational research	Hugo	Botha	United States	Hugo Botha
P342	Unraveling temporal dynamics of brain transcriptome in ALS and ALS-FTD subtypes	10. Translational research	Ting	Shen	United States	Prof. Corey McMillan
P343	Small Molecule Targeting of Chaperone (IP) prevents and reverses TDP-43 aggregation in vitro and in vivo	10. Translational research	Marc	Shenouda	Canada	Dr Marc Shenouda
P344	LSET neurons show overlapping yet distinct gene expression profiles across the cerebral cortex	10. Translational research	Felipe	Pereira	United States	Ph.d. Felipe Pereira
P345	Distinguishing sporadic behavioral-variant frontotemporal dementia from late-onset primary psychiatric disorders with data-driven progression modelling	10. Translational research	Vikram	Venkatraghavan	Netherlands	Dr. Vikram Venkatraghavan
P346	Granulins rescue neuroinflammation, lipofuscinosis, and lysosome dysregulation in a mouse model of progranulin deficiency.	10. Translational research	Thomas	Kukar	United States	Dr. Thomas Kukar
P347	Individual multimodal distances to predict time to disease onset for MAPT, GRN, and C9orf72 carriers.	10. Translational research	Agnès	Pérez-Millan	Spain	Phd Agnès Pérez-Millan
P348	A Multi-omics approach defining the disease trajectory of FrontoTemporal Dementia	10. Translational research	Roberta	Giannelli	Netherlands	Roberta Giannelli
P349	Blood Brain Barrier Penetrant Progranulin Replacement Therapy	10. Translational research	Forest	Andrews	United States	Dr. Forest Andrews
P350	Distinct laminar networks of neuronal covariance in pathologic subgroups of behavioral variant frontotemporal dementia	10. Translational research	Daniel	Ohm	United States	PhD Daniel Ohm

P351	Directional communication among salience, default, and frontoparietal networks support social inference-making in bvFTD	10. Translational research	Yu	Chen	United States	Yu Chen
P352	Impaired glymphatic system in genetic Frontotemporal Dementia: a GENFI study	11. Neuropathology	Enrico	Premi	Italy	Md Enrico Premi
P353	Contribution of skeletal muscle to neuromuscular junction defects in FUS-associated ALS	11. Neuropathology	Anne	Wienand	Belgium	Anne Wienand
P354	Neurovasculature-associated WDR49-positive astrocytes mark protein aggregation and neurodegeneration severity	11. Neuropathology	Ana	Rajcic	Netherlands	MD Ana Rajcic
P355	White Matter Integrity in Primary Progressive Aphasia due to 4R FTLD-tauopathies	11. Neuropathology	Antonia	Zouridakis	United States	Antonia Zouridakis
P356	Sequential neuroanatomical pattern of TAR DNA-binding protein 43 (TDP-43) propagation using imaging and pathological findings	11. Neuropathology	Golnaz	Yadollahikholes	United States	Golnaz Yadollahikholes
P357	Nigral neuronal dysfunction in various conditions associated with astrocytic predominant tau pathology: Nigral Tau-Astroglipathy (NITAG)	11. Neuropathology	Hidetomo	Tanaka	Canada	Hidetomo Tanaka
P358	Progranulin insufficiency and TDP-43 overexpression interact to worsen phenotypes in a mouse model of Frontotemporal Dementia	11. Neuropathology	Anna	Cook	United States	Anna Cook
P359	Differential Vulnerability of the Amygdala to 3R versus 4R FTLD-tauopathies	11. Neuropathology	Rachel	Keszycki	United States	Rachel Keszycki
P360	Investigating TMEM106B's Aggregatin and Impact on Nucleocytoplasmic Transport in an In Vitro Model	11. Neuropathology	Kedamawit	Tilahun	United States	Phd Candidate Kedamawit Tilahun
P361	Activated Microglia in FTLD-TDP Type C	11. Neuropathology	Allegra	Kawles	United States	Allegra Kawles
P362	TDP-43 mislocalization triggers STMN2 cryptic splicing causing reduced mRNA and protein levels in FTD-ALS	11. Neuropathology	Sarat	Vatsavayi	United States	Phd Sarat Vatsavayi
P363	Pathological Associations with the Progression of Frontotemporal Dementia (FTD)	11. Neuropathology	Rogan	Magee	United States	Dr. Rogan Magee
P364	Unprecedented combinations of rare degenerative pathologies in an octogenarian ex-football player	11. Neuropathology	Shelley	Forrest	Canada	Dr Shelley Forrest
P365	Novel glial populations in the pathogenesis of progressive supranuclear palsy	11. Neuropathology	Shelley	Forrest	Canada	Dr Shelley Forrest
P366	DHX9 and hnRNP K are differentially localized in VENs and pyramidal neurons in FTD	11. Neuropathology	Fleur	Schipper	Netherlands	Msc Fleur Schipper
P367	Neuropathological characteristics of a novel CHMP2B mutation	11. Neuropathology	Nina	Fransen	Netherlands	Dr. Nina Fransen
P368	Asymmetric Cortical Neuronal Density and Size in PPA with TDP-43 Proteinopathy: Effect of GRN Mutation	11. Neuropathology	Ivan	Ayala	United States	Ivan Ayala
P369	Longitudinal self-administered smartphone assessments capture cognitive decline and disease progression in presymptomatic and early symptomatic FTLD	11. Neuropathology	Mark	Sanderson-Cimino	United States	Mark Sanderson-Cimino
P370	Divergent Hippocampal Distribution of TDP-43 Pathology in FTLD-TDP vs LATE	11. Neuropathology	Sanaz	Arezoumandan	United States	David Irwin
P371	Characterization of myelin deficits in a rat model with human-like tauopathy	13. Pathophysiological mechanisms	AI	LIU	Canada	Phd AI LIU

P372	A cerebral organoid model of progranulin-associated frontotemporal dementia	13. Pathophysiological mechanisms	Sophie	Goldsmith	United Kingdom	Sophie Goldsmith
P373	The role of TDP-43-associated cryptic exon in KARLN in C9orf72-mediated cortical neurodegeneration	13. Pathophysiological mechanisms	Lauren	Gittings	United States	Dr Lauren Gittings
P374	Progranulin acts in lysosomes to promote neuronal survival and growth	13. Pathophysiological mechanisms	Andrew	Arrant	United States	Andrew Arrant
P376	Baseline in vivo synaptic loss predicts functional decline in frontotemporal lobar degenerative syndromes	13. Pathophysiological mechanisms	Negin	Holland	United Kingdom	Dr Zi Qi Kok
P377	Single-cell RNA-seq reveals striking reduction in peripheral naive CD8+ T cells and LINC02446 in PSP	13. Pathophysiological mechanisms	Phuong	Hoang	United States	Phuong Hoang
P378	Contribution of astrocytic SPARCL1 to cortical synaptic dysfunction in C9orf72-FTD/ALS	13. Pathophysiological mechanisms	Robert	Culibrk	United States	Dr. Robert Culibrk
P379	eIF5 enhances poly-GA RAN translation in C9orf72 FTLD/ALS models	13. Pathophysiological mechanisms	Shiho	Gotoh	Japan	Shiho Gotoh
P380	TDP-43 Regulates Innate Antiviral Signaling and CNS Antimicrobial Defense	13. Pathophysiological mechanisms	Anna	Orr	United States	Dr. Anna Orr
P381	Systematic Review: Electrophysiological Markers in Neurodegeneration	13. Pathophysiological mechanisms	Stéphanie	De Keulenaer	Belgium	Stéphanie De Keulenaer
P382	Altered Expression of Membrane Proteins in C9orf72 Mutation-Associated ALS and FTD	13. Pathophysiological mechanisms	Boris	Rogelj	Slovenia	Prof. Dr. Boris Rogelj
P383	Modelling FTLD-FET using patient-derived induced pluripotent stem cell models	13. Pathophysiological mechanisms	Rafaela	Hasse e Silva Policarpo	Belgium	PhD Rafaela Hasse e Silva Policarpo
P384	Differential neuronal vulnerability to C9orf72 repeat expansion driven by Xbp1 transcription signature	13. Pathophysiological mechanisms	Teresa	Niccoli	United Kingdom	Dr Teresa Niccoli
P385	Profiling Hypothalamic Energy Homeostasis Associated microRNA in DM-1, ALS and Healthy Controls	13. Pathophysiological mechanisms	Claire	Flaherty	United States	Claire Flaherty
P386	White matter pathology in FTD caused by GRN mutations. Review	11. Neuropathology	Hyunwoo	Lee	Canada	Hyunwoo Lee
P404		09. Management	Ines	Martin	Spain	Ines Martin
P405	Fronto-temporal dementia: a case study and strategies and support for caregivers	09. Management	Ines	Martin	Spain	Ines Martin
P406	A Systematic Review of Caregiver Coping Strategies in Frontotemporal Dementia	09. Management	Ines	Martin	Spain	Ines Martin
P407	Global perspectives on speech and language therapy for Primary Progressive	09. Management	Anna	Volkmer	United Kingdom	Dr Anna Volkmer
P408	Group interventions for people with primary progressive aphasia and their care partners: considerations for clinical practice.	09. Management	Anna	Volkmer	United Kingdom	Dr Anna Volkmer
P409	Is intensive speech and language therapy acceptable or feasible for people with primary progressive aphasia?	09. Management	Anna	Volkmer	United Kingdom	Dr Anna Volkmer
P410	Nonverbal social behaviours: Disease specific profiles in primary progressive aphasia.	09. Management	Anna	Volkmer	United Kingdom	Dr Anna Volkmer

P411	Script Club: motivating change through remote group script training for people with primary progressive aphasia	09. Management	Richard	Talbot	United Kingdom	Mr Richard Talbot
P412	An integrative review of the impact of empathy loss on Frontotemporal Dementia Caregivers	09. Management	Lauren	Fisher	United States	Lauren Fisher
P413	Longitudinal changes in functional capacity, cognition, and behaviour in the frontotemporal dementias and Alzheimer's disease	09. Management	David	Foxe	Australia	Dr David Foxe
P414	Targeting What Matters: Personalized goals for persons with primary progressive aphasia and their communication partners	09. Management	Angela	Roberts	Canada	Dr. Angela Roberts
P415	Exploring families' interest in understanding genetic FTD	09. Management	Kim	Jenny	United States	Kim Jenny
P416	The GABAa agonist Zolpidem in Progressive Supra-nuclear Palsy: A case study	09. Management	Emily	Todd	United Kingdom	Miss Emily Todd
P417	A Randomized Clinical Trial of an Educational Intervention to Improve Caregiver Knowledge	09. Management	Katie	Brandt	United States	Katie Brandt
P418	Impact of Advance Care Planning Educational Videos for Dementia Caregivers in the era of COVID-19	09. Management	Erin	Krahn	United States	Erin Krahn
P419	PPA Tele-Savvy: Results of an Online Pilot Intervention with Caregivers of Persons with Primary Progressive Aphasia	09. Management	Darby	Morhardt	United States	Darby Morhardt
P420	Participatory Research among People with Primary Progressive Aphasia: Participant Involvement in the Cope PPA Study	09. Management	Mirjam	Gauch	Germany	Mirjam Gauch
P422	Understanding Caregiving Burdens in Primary Progressive Aphasia: The Role of Conversation Difficulties	09. Management	Angela	Roberts	Canada	Dr. Angela Roberts
P423	Efficacy of acetylcholinesterase inhibitors in the logopenic variant of primary progressive aphasia	09. Management	Julie	Carrier-Auclair	Canada	Julie Carrier-Auclair
P424	Post-diagnostic care pathways in frontotemporal dementia: Experiences and needs of family carers and considerations for interventions	09. Management	Grace	Wei	Australia	Dr Grace Wei
P425	Web-based Speech and Language Therapy approaches to managing individuals with Primary Progressive Aphasia in Italy	09. Management	Petronilla	Battista	Italy	Dr Petronilla Battista
P426	Communication partner training for primary progressive aphasia with a multilingual couple	09. Management	Ingvild Elisabeth	Winsnes	Norway	Miss Ingvild Elisabeth Winsnes
PB1.4 / P004	The influence of cultural background on social cognition in genetic FTD	07. Diversity	Liset	De Boer	Nederland	Liset De Boer
PB3.3 / P281	The Position of Sporadic FTD Cases within the Human Proteomics Neurodegenerative Disease Landscape	10. Translational research	Suzanne	Miedema	Netherlands	Suzanne Miedema
PB4.2 / P128	UNC13A polymorphism shortens survival in behavioural variant frontotemporal dementia	05. Genetics	Lianne	Reus	Netherlands	Phd Lianne Reus
PB4.4 / P126	White Matter Hyperintensities are An Early Biomarker in GRN-related Frontotemporal Dementia	02b. Imaging biomarkers	Mahdie	Soltaninejad	Canada	Phd Candidate Mahdie Soltaninejad
PB5.4 / P277	Behavioural variant frontotemporal dementia and Alzheimer's disease differ in favourite music activation profiles on fMRI	06. Clinic	Jochum	van 't Hooft	Netherlands	MD Jochum van 't Hooft
PB7.3 / P011	Spontaneous speech alterations and evolution in primary progressive aphasia variants	03. Neuropsychology	Elisa	Canu	Italy	PhD Elisa Canu

PB7.4 / P012	The dynamics of auditory working memory impairment in primary progressive aphasia and Alzheimer's disease	03. Neuropsychology	Benjamin	Levett	United Kingdom	PhD Student Benjamin Levett
PB7.5 / P013	Practice effects are reduced within prodromal and symptomatic FTD mutation carriers using the ignite app	03. Neuropsychology	Kerala	Adams-Carr	United Kingdom	Dr Kerala Adams-Carr